hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06386042 id: MEC-2022-0252 briefTitle: Guideline Implementation and Quality of Care in Patients With Heart Failure: the TITRATE-HF Registry acronym: TITRATE-HF overallStatus: ACTIVE_NOT_RECRUITING date: 2022-06-05 date: 2029-02-14 date: 2029-04 date: 2024-04-26 date: 2024-04-26 name: Erasmus Medical Center class: OTHER name: Netherlands Heart Institute briefSummary: SUMMARY Rationale: Quality of Care registries provide valuable insight in guideline adherence and implementation of guideline recommendations in routine clinical practice.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There is no risk in participation, no intervention and no active involvement of patients for specific activities in the study. The project is a registration of care as given (standard care) to the participating subject with heart failure. conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 4289 type: ESTIMATED name: no intervention, observational study measure: Prescription level (percentage,%) and target dose (percentage, %) of guideline-directed medical therapy for HF measure: All-cause mortality measure: Hospital admission due to heart failure related event and/or urgent visit with necessity of furosemide iv. measure: Hospital admission due to non heart failure related event sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus MC city: Rotterdam state: Zuid-Holland zip: 3015CE country: Netherlands lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06386029 id: STUDY24010191 briefTitle: The Power Down Pilot Study: A Novel Bedtime Manipulation Protocol overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2025-05 date: 2024-04-26 date: 2024-04-26 name: University of Pittsburgh class: OTHER briefSummary: The goal of this pilot intervention study is to examine the feasibility and acceptability of a novel bedtime manipulation protocol called "The Power Down" for autistic youth, ages 6-10. The main questions it aims to answer are:
2. Do the families find the Power Down an acceptable intervention to address their child's difficulties settling down to fall asleep? conditions: Autism conditions: Sleep Disturbance studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Pilot, non-blinded intervention trial primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Power Down bedtime manipulation measure: Recruitment rates of participants through the trial measure: Retention rates of participants through the trial measure: Caregiver reported acceptability measure: Treatment adherence measure: Data collection rates- Questionnaires measure: Data collection rates- Daily diaries measure: Data collection rates- Wearing the actigraphy watch measure: Credibility/Expectancy Questionnaire sex: ALL minimumAge: 6 Years maximumAge: 10 Years stdAges: CHILD facility: University of Pittsburgh city: Pittsburgh state: Pennsylvania zip: 15213 country: United States name: Amy G Hartman, PhD role: CONTACT phone: 614-989-6303 email: agh38@pitt.edu lat: 40.44062 lon: -79.99589 hasResults: False
nctId: NCT06386016 id: Stethoscope study briefTitle: Detection of Valvular Heart Disease Using Artificial Intelligence-based Stethoscope overallStatus: RECRUITING date: 2024-05-01 date: 2024-08-01 date: 2024-09-01 date: 2024-04-26 date: 2024-04-26 name: Xiao-dong Zhuang class: OTHER briefSummary: The aim of this study is to develop a deep learning-based application of heart sounds in the diagnosis of valvular heart disease, which can be used to screen patients with valvular heart disease and promote earlier clinical monitoring and intervention. conditions: Valvular Heart Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED name: artificial intelligence-based stethoscope measure: valvular heart disease sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: First Affiliated Hospital, Sun Yat-Sen University status: RECRUITING city: Guangzhou state: Guangdong zip: 510000 country: China name: Xiaodong Zhuang, PhD role: CONTACT phone: +86 13760755035 email: zhuangxd3@mail.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06386003 id: 23-230 briefTitle: Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2025-03 date: 2025-05 date: 2024-04-26 date: 2024-04-26 name: Unity Health Toronto class: OTHER name: Toronto Metropolitan University name: University of Ottawa briefSummary: This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD). conditions: Post Traumatic Stress Disorder conditions: PTSD conditions: Chronic PTSD studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: Psilocybin measure: Feasibility and tolerability measure: Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score measure: Posttraumatic stress disorder Checklist-5 (PCL-5) measure: Patient Health Questionnaire-9 (PHQ-9) measure: Generalized Anxiety Disorder Scale, 7-item (GAD-7) measure: Dissociative Experiences Scale II (DES-II) measure: Pittsburgh Sleep Quality Index (PSQI) measure: World Health Organization Well-Being Index, 5-item (WHO-5) measure: Quality of relationships inventory (QRI) measure: Inventory of psychosocial functioning (IPF) measure: Posttraumatic Maladaptive Beliefs Scale (PMBS) measure: Brief Experiential Avoidance Questionnaire (BEAQ) measure: 24-items Multidimensional Psychological Flexibility Inventory (MPFI-24) measure: Working Alliance Inventory- Short Form (WAI-SF) measure: Difficulties in Emotion Regulation Scale-Short Form (DERS-SF) measure: Self-Compassion Scale-Short Form (SCS-SF) measure: Psychological Insight Questionnaire (PIQ) measure: Emotional Breakthrough Inventory (EBI) measure: Altered States of Consciousness Rating Scale (ASC) measure: Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ) measure: Effect on digital physiological passive data collected through the use of a wearable device sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St. Michael's Hospital, Unity Health Toronto city: Toronto state: Ontario country: Canada lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06385990 id: 2024ks01 briefTitle: Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy overallStatus: RECRUITING date: 2024-03-29 date: 2025-03-29 date: 2027-03-29 date: 2024-04-26 date: 2024-04-26 name: Hunan Cancer Hospital class: OTHER briefSummary: This trial is a multicenter, single-arm clinical trial to evaluate the efficacy and safety of UTD1 in combination with capecitabine for the adjuvant treatment of TNBC patients who did not achieve pathologic complete remission after neoadjuvant therapy. TNBC patients who did not achieve pathological complete remission or positive lymph node after neoadjuvant chemotherapy received adjuvant treatment with study drug.
Solution: UTD1 30mg / m², once a day on days 1-5; capecitabine: 1000mg / m², days 1-14, oral, twice / day; 21 days a treatment cycle of 6-8 cycles. conditions: Triple Negative Breast Neoplasms studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 53 type: ESTIMATED name: UTD1 measure: 2-year disease-free survival (DFS) measure: Overall Survival (OS) measure: Disease Free Survival (DFS) measure: Invasive Disease free survival (iDFS) measure: Distant Disease-free Survival (DDFS) sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Quchang Ouyang status: RECRUITING city: Changsha state: Hunan zip: 410083 country: China name: Quchang Ouyang role: CONTACT phone: 8673189762161 email: oyqc1969@126.com lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06385977 id: ShaanxiPPH briefTitle: Risk Factors for Chronic Prostatitis Patients in Northwest China overallStatus: RECRUITING date: 2016-01 date: 2024-05 date: 2024-06 date: 2024-04-26 date: 2024-04-26 name: Shaanxi Provincial People's Hospital class: OTHER briefSummary: The goal of this observational study is to learn about the risk factors of lifestyle, medication and sexual habits in adult chronic prostatitis / chronic pelvic pain syndrome patients. The main questions it aims to answer are:
Researchers will compare healthy adult males to see if there are differences on lifestyle, medication and sexual habits between the two groups. conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED name: lifestyle name: sexual habits name: medication measure: Odds Ratio sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shaanxi Provincial People's Hospital status: RECRUITING city: Xi'an state: Shaanxi zip: 710061 country: China name: Qian Deng, Doctor role: CONTACT phone: 86-029-85251331 phoneExt: 2079 email: dengqian@xiyi.edu.cn lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06385964 id: SHR-4597-101 briefTitle: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2025-01 date: 2024-04-26 date: 2024-04-26 name: Guangdong Hengrui Pharmaceutical Co., Ltd class: INDUSTRY briefSummary: The primary objective of this randomized, double-blind, single/multiple ascending dose, placebo-controlled Phase I clinical trial was to evaluate the safety and tolerability of SHR-4597 in healthy subjects and asthmatic patients. The study consists of two parts: Part 1 involves single ascending inhalation dose in healthy subjects; Part 2 involves multiple ascending inhalation dose in asthmatic patients, further divided into Part 2A: multiple ascending inhalation dose in mild to moderate asthmatic patients, and Part 2B: multiple ascending inhalation dose in moderate to severe asthmatic patients. Subsequent lung pharmacokinetic studies of SHR-4597 inhalation will be conducted based on patients' PKPD data. conditions: Healthy Subjects conditions: Asthmatic Patients studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: SHR-4597 name: Placebo measure: Incidence and severity of inhalant adverse events after 4 days of single inhalation of SHR4597 in healthy subjects measure: Incidence and severity of inhalant adverse events after 16 days of multiple inhalation of SHR4597 in asthmatic patients, sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385951 id: ONZ-2023-0323 briefTitle: Spatial Navigation for the Early Detection of Alzheimer's Disease. acronym: ALLO-task overallStatus: RECRUITING date: 2024-03-05 date: 2028-03-01 date: 2028-10-01 date: 2024-04-26 date: 2024-04-26 name: University Hospital, Ghent class: OTHER briefSummary: Alzheimer's Disease (AD) is the most common form of dementia and may contribute to 60-70 % of all cases. An early, accurate diagnosis of AD will become increasingly important with disease-modifying therapies. Different types of fluid and neuroimaging biomarkers are available for the early detection of AD. However, implementation of routine use of these biomarkers in clinical settings is held back due to the risk of overdiagnosis, increased cost and invasiveness of the assessment method. Therefore, novel biomarkers are needed beyond the amyloid and tau pathologies for the early diagnosis of AD. Neuropsychological paper and pencil tests can detect AD and discriminate between different clinical stages. Since medial temporal lobe structures, including the hippocampus and entorhinal cortex (EC), are involved in spatial navigation and degenerate in the earliest stages of AD, spatial navigation can be considered as an early cognitive biomarker of the disease. Nonetheless, the measurement of spatial navigation needs further improvement since the current paper and pencil tests lack ecological validity. Therefore, the test environment should be set up in immersive Virtual Reality (iVR). Dr. Andrea Castegnaro (Space and Memory Lab of University College of London) developed the Allocentric Spatial Update Task (ALLO task), which is an iVR task measuring egocentric and allocentric spatial abilities.
Through the Department of Neurology of the University Hospital of Ghent, which has a large cognitive disorders clinic, patients with mild cognitive impairment and mild Alzheimer's dementia will be recruited. Participants will undergo standard clinical assessment, including a neuropsychological examination, Magnetic Resonance Imaging, a 18F-fluorodeoxyglucose PET and a Lumbar Puncture. In addition, participants will also be asked to undergo Tau PET imaging, Amyloid PET imaging and complete the ALLO iVR task. Healthy controls will also be recruited and have to undergo the same investigations, except for the amyloid PET and lumbar puncture. conditions: Mild Cognitive Impairment conditions: Alzheimer Disease conditions: Healthy Aging studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 160 type: ESTIMATED name: Procedure for patients name: Procedure for healthy controls measure: Spatial navigation abilities measure: Medial Temporal Lobe atrophy measure: Amount and spreading of amyloid in the brain measure: Amount and spreading of tau in the brain measure: Decreases in cerebral glucose metabolism in the brain measure: Cognitive functioning measure: amyloidB1-42 / 40 ratio, total tau and phosphorylated tau sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Gent status: RECRUITING city: Ghent state: East-Flanders zip: 9000 country: Belgium name: Tineke Van Vrekhem role: CONTACT phone: 093326483 email: tineke.vanvrekhem@uzgent.be lat: 51.05 lon: 3.71667 hasResults: False
nctId: NCT06385938 id: 23-012048 briefTitle: Ultrasound Imaging and Quantitative Vibro-Acoustic Assessment of Rickets Under the Age of Ten overallStatus: RECRUITING date: 2024-05 date: 2026-04 date: 2026-04 date: 2024-04-26 date: 2024-04-26 name: Mayo Clinic class: OTHER briefSummary: The goal of this study is to find out if the use of ultrasound pictures of bones can spot changes in the growth areas of children with rickets, a condition that affects how bones harden. Researchers want to see if these ultrasound pictures can help tell the difference between children who have rickets and those who don't. conditions: Rickets studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 45 type: ESTIMATED name: Ultrasound with quantitative vibro-acoustic assessment measure: Relationship of quantitative vibro-acoustic ultrasound and rickets severity score measure: Relationship of ultrasound images with radiographic evidence of rickets measure: Case-control comparison of quantitative vibro-acoustic ultrasound measurements between children with rickets and control subjects measure: Longitudinal changes in vibro-acoustic ultrasound measurements with treatment of rickets sex: ALL maximumAge: 10 Years stdAges: CHILD facility: Mayo Clinic Minnesota status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Mary A Johnson role: CONTACT phone: 507-422-6823 email: johnson.mary15@mayo.edu name: Tom D. Thacher, MD role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06385925 id: TSN1611-2023-101 briefTitle: A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation overallStatus: RECRUITING date: 2024-04-30 date: 2026-10-30 date: 2027-04-30 date: 2024-04-26 date: 2024-04-26 name: Tyligand Bioscience (Shanghai) Limited class: INDUSTRY briefSummary: The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. conditions: Malignant Neoplasm studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 150 type: ESTIMATED name: TSN1611 measure: Dose limiting toxicities (DLTs) in phase 1 part measure: Objective response rate (ORR) in phase 2 part measure: Adverse events measure: Area under the plasma concentration-time curve (AUC) measure: Maximum blood concentrations (Cmax) measure: Time to maximum blood concentration (Tmax) measure: Duration of response (DOR) measure: Time to response (TTR) measure: Disease control rate (DCR) measure: Progression free survival (PFS) measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center status: NOT_YET_RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Siqing Fu, MD, PhD role: CONTACT lat: 29.76328 lon: -95.36327 facility: NEXT Oncology status: RECRUITING city: San Antonio state: Texas zip: 78229 country: United States name: David Sommerhalder, MD, PhD role: CONTACT lat: 29.42412 lon: -98.49363 facility: NEXT Virginia status: RECRUITING city: Fairfax state: Virginia zip: 22031 country: United States name: Alexander Spira, MD, PhD role: CONTACT lat: 38.84622 lon: -77.30637 hasResults: False
nctId: NCT06385912 id: 2024-TJ-SLIDS briefTitle: Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer overallStatus: COMPLETED date: 2006-07-01 date: 2021-02-10 date: 2021-02-10 date: 2024-04-26 date: 2024-04-26 name: Tongji Hospital class: OTHER briefSummary: The study aims to investigate the prognostic and postoperative complication relevance of lymphadenectomy in advanced epithelial ovarian cancer patients who received neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). The main question it aims to answer is:
The progression-free survival (PFS), overall survival (OS), and postoperative complication were compared between the lymphadenectomy and no lymphadenectomy groups to answer the question. conditions: Ovarian Cancer conditions: Postoperative Complications conditions: Neoadjuvant Therapy conditions: Lymph Node Excision studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 1090 type: ACTUAL name: lymphadenectomy measure: Progression free survival (PFS) measure: Overall survival (OS) sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology city: Wuhan state: Hubei zip: 430030 country: China lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06385899 id: : Poorly controlled T2DM-12 briefTitle: Effect of Intensive Monitoring of Patients With Poorly Controlled Type 2 Diabetes With Different Glycemic Background overallStatus: COMPLETED date: 2021-08-01 date: 2023-01-01 date: 2023-03-01 date: 2024-04-26 date: 2024-04-26 name: Goztepe Prof Dr Suleyman Yalcın City Hospital class: OTHER briefSummary: In Turkey, only 55% of patients with type 2 diabetes have been diagnosed, and 91% of these patients have been receiving treatment. The rate of patients reaching the treatment target is 50%. The pandemic has also affected diabetic patients. It is aimed to determine the characteristics of patients with type 2 diabetes (HbA1c \>=10) with poor metabolic control and to evaluate the extent to which metabolic control can be achieved in 12 months. conditions: Type 2 Diabetes conditions: Poor Glycemic Control studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 266 type: ACTUAL measure: Changes in HbA1c levels after 12 months treatment measure: percentage of patients who reached the HbA1c target of equal to or below 7% measure: The effect of education on the HbA1c changes measure: The effect of depression on the HbA1c changes measure: The effect of the level of physical activity on the HbA1c changes measure: The effect of weight loss on the HbA1c changes sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istanbul Goztepe Prof. Dr. Suleyman Yalcin City Hospital city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06385886 id: 1R01HL158807-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/1R01HL158807-01A1 briefTitle: Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease acronym: RECIPE overallStatus: RECRUITING date: 2023-06-08 date: 2027-10 date: 2027-12 date: 2024-04-26 date: 2024-04-26 name: RTI International class: OTHER briefSummary: The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assessment survey which will cover areas such as previous and current treatment, clinic and hospital experience, pain, and quality of life. Participants will also be given the option of participation in a 1-hour long interview how they feel about treatment for sickle cell disease including clinic experience, pain, and quality of life? conditions: Sickle Cell Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Linkage Coordinator measure: Identification of unaffiliated patients measure: Affiliation with a Sickle cell disease (SCD)-specific care with SCD specialist measure: Scale Out to Other SCD Centers - Implementation in at least 2 other SCD Center study sites sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama, Birmingham (UAB) status: RECRUITING city: Birmingham state: Alabama zip: 35233 country: United States name: Julie Kanter, MD role: CONTACT phone: 205-934-0435 email: jkanter@uabmc.edu lat: 33.52066 lon: -86.80249 facility: University of California, San Francisco (UCSF) status: RECRUITING city: Oakland state: California zip: 94609 country: United States name: Marsha Treadwell, PhD role: CONTACT phone: 510-428-3356 email: marsha.treadwell@ucsf.edu lat: 37.80437 lon: -122.2708 facility: Augusta University status: RECRUITING city: Augusta state: Georgia zip: 30901 country: United States name: Robert Gibson, PhD role: CONTACT phone: 706-721-1005 email: rogibson@augusta.edu lat: 33.47097 lon: -81.97484 facility: University of Illinois status: RECRUITING city: Chicago state: Illinois zip: 60612 country: United States name: Lewis Hsu, MD, PhD role: CONTACT phone: 312-355-5019 email: lewhsu@uic.edu lat: 41.85003 lon: -87.65005 hasResults: False